Comparative Pharmacology
Head-to-head clinical analysis: CIN QUIN versus QUINALAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIN QUIN versus QUINALAN.
CIN-QUIN vs QUINALAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cin-Quin (quinidine) is a class Ia antiarrhythmic agent that blocks sodium channels, prolonging the effective refractory period and slowing conduction velocity. It also has anticholinergic and alpha-adrenergic blocking properties.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
Quinine sulfate 648 mg (two 324 mg capsules) orally every 8 hours for 7 days, in combination with doxycycline, tetracycline, or clindamycin.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy volunteers; prolonged to 8-12 hours in severe malaria or hepatic impairment.
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; renal excretion of unchanged drug <20%. Biliary/fecal excretion accounts for ~30% of total clearance.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)